Oncolys BioPharma has agreed to purchase an additional 8.4% stake in Precision Virologics from US-based oncolytic virus immunotherapy products developer Unleash Immuno Oncolytics.

As part of the acquisition, Oncolys BioPharma will purchase 294,118 shares of Precision Virologics from Unleash for $0.33m. Oncolys BioPharma’s stake will then increase from the existing 14.6% to 23%.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).”

Oncolys BioPharma is a biopharmaceutical company based in Japan, while Precision Virologics is a biotechnology company based in the US.

Unleash Immuno Oncolytics has simultaneously announced plans to raise $3m through the private placement of convertible bonds.

Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).

Based in the US, Alira Health is an international healthcare and life science advisory firm, while CAP is involved in providing clinical trial management and consulting services.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

NL-HOLDING has acquired ProCrea Group, Archimed and Instituto de Medicina Reproductiva (IMER).

The German healthcare services provider has acquired all three companies in partnership with Oaktree Capital Management.

ProCrea and Instituto de Medicina Reproductiva are assisted-reproduction service providers based in Switzerland and Spain respectively, while Archimedis is an Italian company involved in the provision of specialised diagnostic services.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact